Peptides

CJC-1295/Ipamorelin Research Overview

Research overview of CJC-1295 and ipamorelin, a growth hormone secretagogue combination studied for pulsatile GH release, body composition, and ageing.

CJC-1295 and ipamorelin represent a frequently studied growth hormone (GH) secretagogue combination in research literature. CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue, while ipamorelin is a selective growth hormone secretagogue (ghrelin receptor agonist). When used in combination, they are hypothesised to stimulate pulsatile GH release through complementary mechanisms. This combination has been the subject of preclinical and some clinical research examining effects on GH secretion, body composition, and metabolic function.

Mechanism of Action

CJC-1295: GHRH Analogue

CJC-1295 is a modified form of growth hormone-releasing hormone with several distinct variants in the research literature:

CJC-1295 (modified GRF 1-29 / Mod GRF 1-29)

  • A 29-amino acid peptide corresponding to the first 29 amino acids of GHRH
  • Contains four amino acid substitutions that enhance stability and receptor binding
  • Half-life of approximately 30 minutes
  • Stimulates GH release from the anterior pituitary via GHRH receptors

CJC-1295 with Drug Affinity Complex (DAC)

  • The DAC version includes a reactive chemical group that binds covalently to serum albumin
  • This extends the half-life to approximately 6-8 days
  • Creates more sustained GH elevation compared to the non-DAC version
  • The non-DAC version (modified GRF 1-29) is more commonly discussed in combination with ipamorelin

For the purposes of this overview, the combination with ipamorelin typically refers to modified GRF 1-29 (non-DAC CJC-1295), as this more closely mimics natural GHRH pulsatility.

Ipamorelin: Ghrelin Receptor Agonist

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the receptor for the endogenous hormone ghrelin:

  • Selective GH release: Ipamorelin stimulates GH release without significantly affecting prolactin, cortisol, or ACTH secretion, distinguishing it from non-selective secretagogues
  • Pulsatile mechanism: Ipamorelin triggers GH release through the hypothalamic-pituitary axis, preserving natural pulsatile patterns
  • Synergistic with GHRH: When combined with a GHRH analogue, ipamorelin’s effect on GH release is enhanced, as GHRH primes the somatotrophs while ghrelin receptor activation triggers GH release

Combination Rationale

The combination of CJC-1295 (modified GRF 1-29) and ipamorelin leverages two complementary GH-releasing pathways:

  • GHRH pathway (CJC-1295): Primes and sensitises somatotroph cells, increasing the amount of GH available for release
  • Ghrelin pathway (Ipamorelin): Triggers the actual release event, producing a GH pulse

Together, this combination is hypothesised to produce more robust and physiological GH pulses than either peptide alone, while maintaining the natural feedback mechanisms of the hypothalamic-pituitary axis.

Key Research

Growth Hormone Release

Research into the GH-releasing effects of this combination:

  • In vitro studies: Researchers have observed synergistic GH release when GHRH analogues and ghrelin receptor agonists are combined in pituitary cell cultures
  • Animal models: Preclinical studies have demonstrated enhanced GH pulsatility with combined GHRH and ghrelin receptor agonist administration
  • Human studies: Clinical research has examined GH release patterns following administration of CJC-1295 variants. Teichman et al. (2006) published pharmacokinetic and pharmacodynamic data for CJC-1295 with DAC in the Journal of Clinical Endocrinology and Metabolism

Body Composition

Some research has examined the downstream effects of enhanced GH secretion on body composition:

  • GH is known to promote lipolysis and lean body mass maintenance
  • Researchers have observed modest improvements in body composition parameters in some studies
  • The magnitude of effects appears to be dose-dependent and varies with baseline GH status
  • Results have been mixed, with some studies reporting significant changes and others reporting minimal effects

Sleep and Recovery

An area of interest in community discussion (though limited formal research):

  • GH secretion is naturally highest during deep sleep
  • Some researchers have investigated whether GH secretagogue administration at specific times can enhance sleep-associated GH release
  • Formal clinical data on sleep outcomes specifically with CJC-1295/ipamorelin combinations is limited

Ageing Research

The age-related decline in GH secretion (somatopause) has motivated research into GH secretagogues:

  • Researchers have observed that GH secretagogue levels decline with age
  • Some studies have examined whether restoring GH pulsatility in older adults could reverse aspects of age-related body composition changes
  • The relationship between GH, IGF-1, and ageing is complex, with both deficiency and excess associated with adverse outcomes

Pharmacological Considerations

Dosing Frequency

  • Modified GRF 1-29 (non-DAC CJC-1295): Typically studied with multiple daily doses due to its short half-life (~30 minutes)
  • Ipamorelin: Short half-life, typically co-administered with CJC-1295
  • The DAC version of CJC-1295 allows less frequent dosing but produces more sustained (less pulsatile) GH elevation

GH Feedback

  • Unlike exogenous GH administration, secretagogue combinations preserve the hypothalamic-pituitary feedback loop
  • IGF-1 produced in response to GH release feeds back to suppress further GH release
  • This feedback mechanism may provide a safety advantage over exogenous GH

Australian Research Context

Neither CJC-1295 nor ipamorelin is approved by the TGA for any therapeutic indication. They are not listed on the Australian Register of Therapeutic Goods (ARTG).

The regulatory status of growth hormone secretagogues in Australia should be understood in context:

  • Growth hormone-releasing factors and their analogues are subject to scheduling under the Poisons Standard
  • The importation of research peptides is regulated under the Therapeutic Goods Act 1989
  • Researchers should consult the TGA and relevant legislation for current regulatory guidance

Research Limitations

Important considerations in the CJC-1295/ipamorelin research landscape:

  • Formal randomised controlled trials in healthy populations are limited
  • Much of the supporting evidence comes from GH physiology research rather than studies specifically examining the combination
  • The magnitude of body composition effects in non-GH-deficient individuals is uncertain
  • Long-term safety data is not established
  • The distinction between CJC-1295 variants (DAC vs non-DAC) in research literature is sometimes unclear, complicating interpretation
  • Most body composition studies are short-term and small-scale
  • Individual responses may vary significantly based on age, baseline GH status, and other factors
  • Tesamorelin - A GHRH analogue with TGA-approved indication for HIV-associated lipodystrophy
  • MOTS-c - A mitochondrial-derived peptide studied in metabolic and exercise research
  • GLP-1 Peptides - Overview of GLP-1 receptor agonist research
  • Retatrutide - A triple agonist studied in metabolic and obesity research

For research literacy and educational purposes only. This content does not constitute medical advice or therapeutic recommendation. Consult a qualified healthcare professional for medical decisions.